Crummy Elizabeth A, O'Neal Timothy J, Baskin Britahny M, Ferguson Susan M
Graduate Program in Neuroscience, University of Washington, Seattle, WA, United States.
Center for Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, WA, United States.
Front Neurosci. 2020 Jun 16;14:569. doi: 10.3389/fnins.2020.00569. eCollection 2020.
Substance use disorder (SUD) is a chronic, relapsing disease with a highly multifaceted pathology that includes (but is not limited to) sensitivity to drug-associated cues, negative affect, and motivation to maintain drug consumption. SUDs are highly prevalent, with 35 million people meeting criteria for SUD. While drug use and addiction are highly studied, most investigations of SUDs examine drug use in isolation, rather than in the more prevalent context of comorbid substance histories. Indeed, 11.3% of individuals diagnosed with a SUD have concurrent alcohol and illicit drug use disorders. Furthermore, having a SUD with one substance increases susceptibility to developing dependence on additional substances. For example, the increased risk of developing heroin dependence is twofold for alcohol misusers, threefold for cannabis users, 15-fold for cocaine users, and 40-fold for prescription misusers. Given the prevalence and risk associated with polysubstance use and current public health crises, examining these disorders through the lens of co-use is essential for translatability and improved treatment efficacy. The escalating economic and social costs and continued rise in drug use has spurred interest in developing preclinical models that effectively model this phenomenon. Here, we review the current state of the field in understanding the behavioral and neural circuitry in the context of co-use with common pairings of alcohol, nicotine, cannabis, and other addictive substances. Moreover, we outline key considerations when developing polysubstance models, including challenges to developing preclinical models to provide insights and improve treatment outcomes.
物质使用障碍(SUD)是一种慢性复发性疾病,其病理高度复杂,包括(但不限于)对药物相关线索的敏感性、消极情绪以及维持药物使用的动机。SUD非常普遍,有3500万人符合SUD的标准。虽然对药物使用和成瘾进行了大量研究,但大多数对SUD的调查都是孤立地研究药物使用,而不是在更普遍的共病物质使用史背景下进行。事实上,11.3%被诊断为SUD的个体同时患有酒精和非法药物使用障碍。此外,患有某种物质的SUD会增加对其他物质产生依赖的易感性。例如,酒精滥用者患海洛因依赖的风险增加两倍,大麻使用者增加三倍,可卡因使用者增加15倍,处方药物滥用者增加40倍。鉴于多物质使用的普遍性和风险以及当前的公共卫生危机,通过共同使用的视角来研究这些障碍对于可转化性和提高治疗效果至关重要。不断升级的经济和社会成本以及药物使用的持续增加,激发了人们对开发能够有效模拟这一现象的临床前模型的兴趣。在这里,我们回顾了该领域在理解酒精、尼古丁、大麻和其他成瘾物质共同使用背景下的行为和神经回路方面的现状。此外,我们概述了开发多物质模型时的关键考虑因素,包括开发临床前模型以提供见解和改善治疗结果所面临的挑战。